Journals
Publish with us
Publishing partnerships
About us
Blog
Canadian Journal of Gastroenterology and Hepatology
Journal overview
For authors
For reviewers
For editors
Table of Contents
Special Issues
Canadian Journal of Gastroenterology and Hepatology
/
2016
/
Article
/
Tab 50
/
Meeting Abstracts
Program and Abstracts from the Canadian Digestive Diseases Week
2016
Table 50
Patient demographics and clinical outcomes.
Early Anti-TNF
Late Anti-TNF
(%)
57 (49.6)
58 (50.4)
Infliximab (%)
40 (70.2)
38 (65.5)
0.59
Adalimumab (%)
17 (29.8)
20 (34.5)
Median time to anti-TNF (weeks, IQR)
38.1 (23.3–91.0)
414.0 (254.0–561.3)
<0.001
Active or former smoker (%)
11 (19.3)
15 (25.9)
0.76
Pancolitis (%)
43 (75.4)
40 (69.0)
0.44
Endoscopic mayo score at anti-TNF (mean, ±SD)
2.46 (±0.66)
1.86 (±0.67)
<0.001
Colectomy (%)
10 (17.5)
5 (8.6)
0.16
UC-related hospitalization
25 (43.9)
16 (27.6)
0.07
Clinical loss of response
28 (49.1)
34 (58.6)
0.31